Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews

No studies found 0 · 0%GRADE not reported 1 · 14.3%Very low 2 · 28.6%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

All‐cause mortality · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 88 participants
Very low

All‐cause mortality · children with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

All‐cause mortality · children with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

All‐cause mortality · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 540 participants
Low

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Serious adverse events (including mortality) · adults and children with chronic asthma

Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
OR 0.8 [0.49, 1.31]
8 studies · 854 participants
Low

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low